Trial Profile
Comparisons of changes in circulating vascular endothelial growth factor-A and renal vascular parameters after intravitreal ranibizumab or aflibercept for retinal vascular disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration; Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- 01 Apr 2017 New trial record